Groundbreaking Treatment for Metastatic Uveal Melanoma Approved for Use in the UK

Contributed by: PA Media Press Centres

Logo

Ocular Melanoma UK

Images

Jo Gumbs, CEO and Founder of Ocular Melanoma UK

Megan, a patient who received Tebentafusp, a pioneering treatment for metastatic uveal melanoma, that is now available to patients in the UK

Tags

Ocular Melanoma UK

Eye Cancer

More Like This

Amgen’s TEPEZZA®▼ (teprotumumab) Granted Marketing Authorisation as the First Targeted Treatment Specifically for Adults With Moderate-to-severe Thyroid Eye Disease (TED) in the United Kingdom

MHRA Approves Zolbetuximab

BeiGene Receives FDA Approval for TEVIMBRA® for the Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy

Petosemtamab granted Breakthrough Therapy Designation by the U.S. FDA

European Commission Approves BeiGene’s TEVIMBRA for First-Line Treatment of Advanced/Metastatic Esophageal Squamous Cell Carcinoma and Gastric or Gastroesophageal Junction Cancer

PR Newswire associated0

Calyx Medical Imaging Supports Groundbreaking Melanoma Treatment Approval

Petosemtamab granted Breakthrough Therapy designation by the U.S. FDA for 1L PD-L1 positive head and neck squamous cell carcinoma

PR Newswire associated0

Qilu Pharmaceutical announces the latest results from its clinical study on QL1706, in combination with chemotherapy, as a first-line treatment for recurrent or metastatic cervical cancer